LOGIN  |  REGISTER
Terns Pharmaceuticals

BUY $TERN

Buy $TERN on Charles Schwab

Buy $TERN on ETrade

Buy $TERN on Public.com

Buy $TERN on Fidelity

Buy $TERN on  Robinhood

Buy $TERN on Webull

Terns Pharmaceuticals to Participate in Upcoming June Investor Conferences

May 30, 2024 | Last Trade: US$5.71 0.11 1.96

FOSTER CITY, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small molecule product candidates to address serious diseases, including oncology and obesity, today announced that members of senior management will be participating in the following upcoming investor conferences in June.

Jefferies Global Healthcare Conference
Format: Fireside Chat         
Date and Time: Wednesday, June 5, 2024 at 5:00 p.m ET
Location: Marriott Marquis, New York City

Goldman Sachs 45th Annual Global Healthcare Conference
Format: Fireside Chat
Date and Time: Tuesday, June 11, 2024 at 3:20 p.m. ET
Location: Loews Miami Beach Hotel, Miami

Live webcasts of the fireside chats will be available on the investor relations page of the Terns Pharmaceuticals website at http://ir.ternspharma.com. A replay of the webcasts will be archived on Terns’ website for at least 30 days following the presentations.

About Terns Pharmaceuticals

Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a portfolio of small molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline includes three clinical-stage development programs including an allosteric BCR-ABL inhibitor, a small molecule GLP-1 receptor agonist, a THR-β agonist, and a preclinical GIPR modulator discovery effort, prioritizing a GIPR antagonist nomination candidate. For more information, please visit: www.ternspharma.com

Contacts for Terns

Investors
Justin Ng
This email address is being protected from spambots. You need JavaScript enabled to view it.

Media
Jenna Urban
Berry & Company Public Relations
This email address is being protected from spambots. You need JavaScript enabled to view it.

BUY $TERN

Buy $TERN on Charles Schwab

Buy $TERN on ETrade

Buy $TERN on Public.com

Buy $TERN on Fidelity

Buy $TERN on  Robinhood

Buy $TERN on Webull

Stock Quote

BUY $TERN

Buy $TERN on Charles Schwab

Buy $TERN on ETrade

Buy $TERN on Public.com

Buy $TERN on Fidelity

Buy $TERN on  Robinhood

Buy $TERN on Webull

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE
Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB